What is Beijing Science Sun Pharmaceutical Co Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Beijing Science Sun Pharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Beijing Science Sun Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Beijing Science Sun Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:
SZSE:300485'
s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
During the past 13 years, Beijing Science Sun Pharmaceutical Co's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.
Beijing Science Sun Pharmaceutical Co Cash-to-Debt Historical Data
The historical data trend for Beijing Science Sun Pharmaceutical Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Beijing Science Sun Pharmaceutical Co Cash-to-Debt Chart
|
Beijing Science Sun Pharmaceutical Co Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
No Debt |
No Debt |
No Debt |
No Debt |
No Debt |
|
Beijing Science Sun Pharmaceutical Co Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
No Debt |
No Debt |
No Debt |
No Debt |
No Debt |
Competitive Comparison of Beijing Science Sun Pharmaceutical Co's Cash-to-Debt
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Science Sun Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Science Sun Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Science Sun Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Beijing Science Sun Pharmaceutical Co's Cash-to-Debt falls into.
Beijing Science Sun Pharmaceutical Co Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Beijing Science Sun Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Beijing Science Sun Pharmaceutical Co had no debt (1).
Beijing Science Sun Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
Beijing Science Sun Pharmaceutical Co had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Science Sun Pharmaceutical Co (SZSE:300485) Business Description
Traded in Other Exchanges
N/A
Address
No. 8, Xingsheng Street, Yizhuang Economic and Technological Development Zone, Beijing, CHN, 100176
Beijing Science Sun Pharmaceutical Co Ltd is engaged in the research and development, production and sales of biological drugs. The company products can be divided into cardiovascular series, immune regulation series, nervous system series, and other natural or biotech pharmaceuticals. Its products include Injection Tiopronin, Cybex, Xel, Lichinga, Plasmin Injection and Race liter.
Executives
Beijing Science Sun Pharmaceutical Co (SZSE:300485) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300485 has been successfully added to your